About DEMECAN
DEMECAN is a Healthcare company based in Berlin (Germany) founded in 2017 by Constantin Von Der Groeben, Adrian Fischer, and Cornelius Maurer. Producer of medical cannabis. DEMECAN has raised $7.64 million across 1 funding round from investors including b2venture. Its website demecan.de draws about 22 thousand monthly visits. DEMECAN offers products and services including Medical Cannabis Products, Patientenausweis, and Apotheken-Finder. Its focus areas include HealthTech, Cannabis HealthTech and Nutraceuticals.
Company details
DEMECAN, backed by 7641380.0 from b2venture, focuses on healthtech, cannabis healthtech, providing healthcare solutions, and nutraceuticals. Producer of medical cannabis. Driving innovation, growth, and excellence in its industry sectors. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Berlin, Germany
- Founders Constantin Von Der Groeben, Adrian Fischer, Cornelius Maurer
- SectorsHealthcare
- Website category Health · Addictions
- Emailβ’β’β’β’β’β’β’β’
- Website demecan.de
- Social LinkedIn X Instagram
- Total Equity Funding$7.64M (USD)
in 1 rounds
- Latest Funding Round$7.64M (USD), Series A
Oct 2019
- Investors
Products & Services of DEMECAN
DEMECAN offers a comprehensive portfolio of products and services, including Medical Cannabis Products, Patientenausweis, and Apotheken-Finder.
High-quality cannabis for medical therapy and patient treatment
Secure digital ID for identifying medical cannabis patients
Tool to locate pharmacies offering cannabis-related services
Funding Insights of DEMECAN
DEMECAN has successfully raised a total of $7.64M through 1 strategic funding round. The most recent funding activity was a Series A round of $7.64 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.64M
- Total Rounds 1
- Last Round Series A β $7.64M
- First Round $7.64M
(Oct 2019)
- Investors Count 1
All 1 funding rounds of DEMECAN with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2019 | $7.64M | Series A | β | b2venture | β |
1 investors in total: 1 institutional.
Investors in DEMECAN
DEMECAN has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include b2venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is provided to innovative startups by b2venture. | b2venture.vc | St. Gallen, Switzerland |
Investor details for DEMECAN
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of DEMECAN
9 people are tracked at DEMECAN (4 in leadership, 4 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Constantin Von Der Groeben | Co-Founder & Managing Director | Leadership |
Adrian Fischer | Co-Founder & Managing Director | Leadership |
Cornelius Maurer | Co-Founder & Managing Director | Leadership |
Dr. Cornelius Maurer | Founder & Board Member | Leadership |
Dennis Stracke | Advisor | Board & advisors |
Thomas Herdegen | Advisor | Board & advisors |
Kirsten Müller-Vahl | Advisor | Board & advisors |
Joachim Nadstawek | Advisor | Board & advisors |
Valentin Rieß | Motherplant and Propagation Manager | Team |
Complete people profiles for DEMECAN
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of DEMECAN
2 dated milestones of DEMECAN across 2 years, from founding to its latest funding, stage changes and deals.
- Founded DEMECAN is founded.
- Funding First funding round of $7.6M.
Web traffic of DEMECAN
The website of DEMECAN (demecan.de) receives about 21.8K visits a month and ranks #2,684,830 among all websites worldwide, #2,912 in Addictions.
- Monthly visits21.8K
▲ 150.7% vs previous month
- Unique visitors4.7K
per month
- Global rank#2,684,830
among all websites
- Category rank#2,912
Health · Addictions
- Bounce rate77%
- Pages per visit1.4
- Average visit1 min 10 sec
- DevicesDesktop 39% Β· Mobile 61%
Websites whose visitors overlap most with DEMECAN. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
canifyclinics.com | canifyclinics.com | 100% | #1,429,528 | β | |
cannalivery.com | cannalivery.com | 98% | #2,507,004 | β | |
cann24.de | cann24.de | 94% | #1,875,852 | β | |
| avaay.de | 93% | 102.3K | #525,140 | View details | |
gruenebluete.de | gruenebluete.de | 89% | β | ||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 20 similar websites and full traffic analytics for DEMECAN
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 20 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Demecan
Complete news archive for DEMECAN
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DEMECAN
DEMECAN was founded in 2017 and raised its 1st funding round 2 years after it was founded.
DEMECAN is headquartered in Berlin, Germany. It is registered at Berlin, Berlin, Germany.
DEMECAN is a funded company, having raised a total of $7.64M across 1 funding round to date. The company's 1st funding round was a Series A of $7.64M, raised on Oct 2019.
DEMECAN, backed by 7641380.0 from b2venture, focuses on healthtech, cannabis healthtech, providing healthcare solutions, and nutraceuticals. Producer of medical cannabis. Driving innovation, growth, and excellence in its industry sectors. It continues to evolve, meeting industry challenges with strategic approaches.
DEMECAN offers Medical Cannabis Products, Patientenausweis, and Apotheken-Finder.
DEMECAN has 1 investor. Key investors include b2venture.

